Evidence map›Paper›PMID 27227314›Full record

ArticleACS chemical biology2016

Structural and Functional Analysis of the Allosteric Inhibition of IRE1α with ATP-Competitive Ligands.

Hannah C Feldman, Michael Tong, Likun Wang, Rosa Meza-Acevedo, Theodore A Gobillot, Ivan Lebedev, Micah J Gliedt, Sanjay B Hari, Arinjay K Mitra, Bradley J Backes and 3 more

Open access · greenAbstract read
In one paragraph

Article in ACS chemical biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 85 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Advances in pyrazolo[1,5-RSC advances · 2025
    Review
  5. Review
  6. Dual RNase activity of IRE1 as a target for anticancer therapies.Journal of cell communication and signaling · 2023
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Structure-Based Drug Discovery of IRE1 Modulators.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Hannah C FeldmanDepartment of Chemistry, University of Washington , Seattle, Washington, United States.
Michael TongDepartment of Pharmacological Sciences, Stony Brook University Medical School , Stony Brook, New York, United States.
Likun WangDepartment of Medicine, University of California-San Francisco , San Francisco, California, United States.
Rosa Meza-AcevedoDepartment of Medicine, University of California-San Francisco , San Francisco, California, United States.
Theodore A GobillotDepartment of Chemistry, University of Washington , Seattle, Washington, United States.
Ivan LebedevDepartment of Pharmacological Sciences, Stony Brook University Medical School , Stony Brook, New York, United States.
Micah J GliedtDepartment of Medicine, University of California-San Francisco , San Francisco, California, United States.
Sanjay B HariDepartment of Chemistry, University of Washington , Seattle, Washington, United States.
Arinjay K MitraDepartment of Chemistry, University of Washington , Seattle, Washington, United States.
Bradley J BackesDepartment of Medicine, University of California-San Francisco , San Francisco, California, United States.
Feroz R PapaDepartment of Medicine, University of California-San Francisco , San Francisco, California, United States.
Markus A SeeligerDepartment of Pharmacological Sciences, Stony Brook University Medical School , Stony Brook, New York, United States.
Dustin J MalyDepartment of Chemistry, University of Washington , Seattle, Washington, United States.
University of Washington · USStony Brook University · USUniversity of California, San Francisco · USQB3 · US

Funding

University of Washington Medical Scientist Training Program: MD/PhDT32GM007266 · NIGMS · UNIVERSITY OF WASHINGTON · PI HORWITZ, MARSHALL S. · 1985 to 2023
$30.4M
Targeting Epithelial Cells To Treat Pulmonary FibrosisP01HL108794 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PAPA, FEROZ R · 2012 to 2016
$12.6M
Dynamics of Ligand Binding and Protein Kinase Regulation_RenewalR35GM119437 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI Markus A Seeliger · 2016 to 2026
$6.5M
New Molecular Probes For Protein KinasesR01GM086858 · NIGMS · UNIVERSITY OF WASHINGTON · PI MALY, DUSTIN J · 2008 to 2025
$5.5M
Pharmacological Validation of IRE1 for Diabetes MellitusR01DK100623 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BACKES, BRADLEY J, MALY, DUSTIN J · 2014 to 2022
$4.6M
Cytoprotection of Beta Cells Through Modulation of Ire1Alpha FunctionR01DK080955 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PAPA, FEROZ R · 2009 to 2017
$3.0M
Attenuating ER and oxidative stress signaling to reduce cell degeneration in vivoR01DK095306 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI OAKES, SCOTT A., PAPA, FEROZ R · 2013 to 2016
$1.5M
NHLBI NIH HHS P01 HL108794NIDDK NIH HHS R01 DK080955NIDDK NIH HHS R01 DK095306NIDDK NIH HHS R01 DK100623NIGMS NIH HHS R01 GM086858NIGMS NIH HHS R35 GM119437NIGMS NIH HHS T32 GM007266Wellcome Trust
6 · The paper itself

Abstract

The accumulation of unfolded proteins under endoplasmic reticulum (ER) stress leads to the activation of the multidomain protein sensor IRE1α as part of the unfolded protein response (UPR). Clustering of IRE1α lumenal domains in the presence of unfolded proteins promotes kinase trans-autophosphorylation in the cytosol and subsequent RNase domain activation. Interestingly, there is an allosteric relationship between the kinase and RNase domains of IRE1α, which allows ATP-competitive inhibitors to modulate the activity of the RNase domain. Here, we use kinase inhibitors to study how ATP-binding site conformation affects the activity of the RNase domain of IRE1α. We find that diverse ATP-competitive inhibitors of IRE1α promote dimerization and activation of RNase activity despite blocking kinase autophosphorylation. In contrast, a subset of ATP-competitive ligands, which we call KIRAs, allosterically inactivate the RNase domain through the kinase domain by stabilizing monomeric IRE1α. Further insight into how ATP-competitive inhibitors are able to divergently modulate the RNase domain through the kinase domain was gained by obtaining the first structure of apo human IRE1α in the RNase active back-to-back dimer conformation. Comparison of this structure with other existing structures of IRE1α and integration of our extensive structure activity relationship (SAR) data has led us to formulate a model to rationalize how ATP-binding site ligands are able to control the IRE1α oligomeric state and subsequent RNase domain activity.

Indexed as

Adenosine TriphosphateAllosteric RegulationBinding, CompetitiveEndoplasmic Reticulum StressEndoribonucleasesHumansLigandsMolecular StructureProtein Kinase InhibitorsProtein Serine-Threonine KinasesRibonucleasesStructure-Activity RelationshipAdenosine TriphosphateEndoribonucleasesERN1 protein, humanLigandsProtein Kinase InhibitorsProtein Serine-Threonine KinasesRibonucleases

Identifiers

PMID27227314
PMCPMC4992410
OpenAlexW2406605691

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.